The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The Opportunities and Challenges of Gene Therapy for Treatment of Inherited Forms of Vision and Hearing Loss
Open accessAbstract
Inherited forms of blindness and deafness are highly prevalent and severe conditions that significantly impact the lives of millions of people worldwide. The lack of therapeutic options for these conditions poses a major socioeconomic burden. Over the last decades, gene therapy has proven to be a life changing treatment for hereditary and acquired forms of diseases, and extensive preclinical investigation in animal models of both retinal and inner ear disorders has highlighted promising translational opportunities for these disorders too. This led to dozens of clinical trials investigating the efficiency of gene therapy-based approaches, with some of the products for retinal conditions successfully reaching phase III of development or even market authorization. However, challenges remain for the use of gene therapy, which are related to both the features of the delivery vehicles currently available and characteristics of the retinal and inner ear disorders targeted. Therefore, further developments in gene therapy platforms' design, including exploitation of novel technologies such as genome editing, RNA-targeted therapies, and optogenetics, are actively ongoing, driving the field forward. In this study, we review the ongoing applications and achievements of gene therapy for treatment of inherited forms of blindness and deafness as well as the developments that are being pursued in the field to overcome the current limitations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Gene therapy with AAV vectors is being widely explored for inherited retinal diseases given their ability to efficiently transduce photoreceptors and their good safety and efficacy profiles in humans.
“Gene therapy with adeno-associated viral (AAV) vectors is being widely explored for treatment of inherited retinal diseases given their ability to efficiently transduce photoreceptors and their good safety and efficacy profiles in humans (4).”
From Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models (2025) · cites this paper as [4]
Citations
Cites
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni
Kim, E., Koo, T., Park, S. W., Kim, D., Kim, K., Cho, H.-Y., Song, D. W., Lee, K. J., Jung, M. H., Kim, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14500 · Cited by 715
Partial recovery of visual function in a blind patient after optogenetic therapy
Sahel, J.-A., Boulanger-Scemama, E., Pagot, C., Arleo, A., Galluppi, F., Martel, J. N., Esposti, S. D., Delaux, A., de Saint Aubert, J.-B., de Montleau, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01351-4 · Cited by 700
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
Flagged first, then by citations
Research works printed but not linked: 67
- 10.1152/physrev.00035.2019 · DOI
- 10.3389/fgeed.2021.737632 · DOI
- 10.1016/j.preteyeres.2021.101029 · DOI
- 10.1038/s41576-023-00597-7 · DOI
- Cehajic-Kapetanovic J, 2022, Nat Biomed Eng, 1
- 10.1016/j.preteyeres.2014.08.001 · DOI
- 10.3389/fnins.2021.652215 · DOI
- FDA approves hereditary blindness gene therapy, 2018, Nat Biotechnol, 36
- Mendes BB, 2022, Nat Rev Methods Prim, 2, 1, 10.1038/s43586-021-00091-6 · DOI
- 10.1038/s41573-019-0012-9 · DOI · Paper page
- Bulcha JT, 2021, Signal Transduct Target Ther, 6, 1, 10.1038/s41392-021-00487-6 · DOI · Paper page
- 10.2147/TACG.S383453 · DOI · Paper page
- 10.1016/j.coviro.2014.07.008 · DOI
- 10.1016/j.heares.2020.108092 · DOI
- 10.1016/j.molmed.2018.06.006 · DOI · Paper page
- 10.1016/j.preteyeres.2018.08.003 · DOI
- 10.1055/a-1384-0818 · DOI
- 10.1016/j.visres.2023.108258 · DOI
- 10.1167/iovs.64.7.39 · DOI · Paper page
- 10.15252/emmm.201809396 · DOI · Paper page
- 10.1073/pnas.1817537116 · DOI · Paper page
- 10.1016/j.cell.2006.08.040 · DOI
- 10.1055/s-0041-1730410 · DOI
- 10.3390/jcm12031046 · DOI
- 10.1016/j.ymthe.2023.02.001 · DOI
- 10.1097/MOP.0000000000001273 · DOI
- 10.1007/s10162-022-00866-y · DOI
- 10.3389/fnins.2023.1177791 · DOI
- 10.1038/s41598-021-81093-y · DOI
- 10.1007/s00439-016-1648-8 · DOI
- 10.1016/j.preteyeres.2022.101110 · DOI · Paper page
- 10.1177/25158414221134602 · DOI
- Leroy BP, 2022, Invest Ophthalmol Vis Sci, 63, 4536
- 10.26508/lsa.202201592 · DOI
- 10.1038/s41581-022-00636-2 · DOI
- 10.1126/science.abb1400 · DOI
- 10.1038/s41589-021-00868-6 · DOI
- 10.1038/mt.2015.220 · DOI
- 10.1089/crispr.2021.0141 · DOI
- 10.1038/s41433-022-02169-1 · DOI
- Tan E, 2001, Investig Ophthalmol Vis Sci, 42, 589
- 10.1073/pnas.96.2.736 · DOI
- 10.1038/s41467-022-29550-8 · DOI
- 10.1038/nature20565 · DOI · Paper page
- 10.1038/s41467-019-14181-3 · DOI
- 10.1038/s41591-018-0327-9 · DOI · Paper page
- 10.1038/nature25164 · DOI · Paper page
- 10.1038/s41591-019-0500-9 · DOI
- 10.1016/j.omtn.2022.07.016 · DOI
- 10.7150/thno.67781 · DOI
- 10.1016/j.celrep.2022.111061 · DOI
- 10.1038/s41551-019-0501-5 · DOI
- 10.1038/s41551-020-00632-6 · DOI
- 10.1016/j.ymthe.2021.07.011 · DOI · Paper page
- 10.1016/j.ymthe.2023.06.007 · DOI
- 10.1038/s41551-021-00788-9 · DOI
- Kuang J, 2021, Methods, 194
- 10.1038/s41551-022-00911-4 · DOI
- 10.1089/genbio.2022.0015 · DOI
- 10.1089/hum.2019.220 · DOI · Paper page
- 10.1093/protein/gzu028 · DOI · Paper page
- 10.1016/j.preteyeres.2022.101065 · DOI
- 10.1016/j.preteyeres.2022.101089 · DOI
- 10.1016/j.neuron.2006.02.026 · DOI
- 10.1016/j.omtm.2020.06.019 · DOI
- 10.1016/j.omtm.2018.06.006 · DOI · Paper page
- 10.1016/j.visres.2023.108192 · DOI
Cited by
Sorted by citations
Ferla, R., Pugni, E., Lupo, M., Tiberi, P., Fioretto, F., Perota, A., Duchi, R., Lagutina, I., Gesualdo, C., Rossi, S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt9354 · Cited by 19
Self-citation
Metadata
- Authors
- Simons, E. J., & Trapani, I.
- Affiliations
- Akouos, Inc., Boston, Massachusetts, USA.
- Federico II University Hospital (IT)
- Corresponding author
- Trapani, Ivana
- ORCID
- Trapani, Ivana
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2023-09-01
- Volume
- 34
- Issue
- 17-18
- Pages
- 808-820
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W4386246621
- Cited by
- 14
- References
- 4
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 7 · 2023: 1
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- gene therapy, inherited blindness, hereditary hearing loss, retinal disease, inner ear disorders, gene delivery vectors, genome editing, RNA-targeted therapeutics, optogenetics, clinical trials, translational research
- MeSH terms
- Animals, Blindness, Deafness, Genetic Therapy, Hearing Loss, Deaf-Blind Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review